Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca.

de Oliveira JK, Williams DL, Bollmann C, de Seabra NM, Bortolini M, Montiani-Ferreira F.

Vet Ophthalmol. 2019 Feb 6. doi: 10.1111/vop.12634. [Epub ahead of print]

PMID:
30724448
2.

Measurement of serum macrophage migration inhibitory factor (MIF) and correlation with severity and pruritus scores in client owned dogs with atopic dermatitis.

Gow DJ, Jackson H, Forsythe P, Gow AG, Mellanby RJ, Hume DA, Nuttall T.

Vet Dermatol. 2019 Jan 23. doi: 10.1111/vde.12721. [Epub ahead of print]

PMID:
30672038
3.

Urticaria pigmentosa-like skin disease in a domestic shorthair cat.

Tomich LM, Pieper JB.

JFMS Open Rep. 2019 Jan 7;5(1):2055116918821197. doi: 10.1177/2055116918821197. eCollection 2019 Jan-Jun.

4.
5.

Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.

Banovic F, Tarigo J, Gordon H, Barber JP, Gogal RM Jr.

Vet Dermatol. 2019 Feb;30(1):17-e6. doi: 10.1111/vde.12698. Epub 2018 Nov 12.

PMID:
30417482
6.

Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro.

Jasiecka-Mikołajczyk A, Jaroszewski JJ, Maślanka T.

Res Vet Sci. 2018 Dec;121:124-129. doi: 10.1016/j.rvsc.2018.10.014. Epub 2018 Oct 29.

PMID:
30391724
7.
8.

A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA.

Souza CP, Rosychuk RAW, Contreras ET, Schissler JR, Simpson AC.

Vet Dermatol. 2018 Dec;29(6):489-e164. doi: 10.1111/vde.12682. Epub 2018 Aug 23.

PMID:
30141223
9.

Clinical and histopathological features of Burkholderia cepacia complex dermatitis in dogs: a series of four cases.

Cain CL, Cole SD, Bradley Ii CW, Canfield MS, Mauldin EA.

Vet Dermatol. 2018 Oct;29(5):457-e156. doi: 10.1111/vde.12677. Epub 2018 Aug 14.

PMID:
30109733
10.

A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs.

Marsella R, Ahrens K.

Vet Dermatol. 2018 Oct;29(5):439-e146. doi: 10.1111/vde.12660. Epub 2018 Jun 21.

PMID:
29926994
11.

TREATMENT SUCCESS IN THREE ANDEAN BEARS (TREMARCTOS ORNATUS) WITH ALOPECIA SYNDROME USING OCLACITINIB MALEATE (APOQUEL®).

Drake GJ, Nuttall T, López J, Magnone W, Leclerc A, Potier R, Lécu A, Guézénec M, Kolter L, Nicolau A, Lemberger K, Pin D, Cosgrove SB.

J Zoo Wildl Med. 2017 Sep;48(3):818-828. doi: 10.1638/2016-0239.1.

PMID:
28920784
12.

A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib.

Aymeric E, Bensignor E.

Vet Dermatol. 2017 Oct;28(5):512-e123. doi: 10.1111/vde.12458. Epub 2017 Jun 20.

PMID:
28635010
13.

The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.

Simpson AC, Schissler JR, Rosychuk RAW, Moore AR.

Vet Dermatol. 2017 Oct;28(5):485-e113. doi: 10.1111/vde.12450. Epub 2017 May 17.

PMID:
28513001
14.

Concurrent infection with porcine reproductive and respiratory syndrome virus and Haemophilus parasuis in two types of porcine macrophages: apoptosis, production of ROS and formation of multinucleated giant cells.

Kavanová L, Matiašková K, Levá L, Štěpánová H, Nedbalcová K, Matiašovic J, Faldyna M, Salát J.

Vet Res. 2017 May 4;48(1):28. doi: 10.1186/s13567-017-0433-6.

15.

JAK inhibitors in dermatology: The promise of a new drug class.

Damsky W, King BA.

J Am Acad Dermatol. 2017 Apr;76(4):736-744. doi: 10.1016/j.jaad.2016.12.005. Epub 2017 Jan 28. Review.

16.

Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.

Fukuyama T, Ganchingco JR, Bäumer W.

Eur J Pharmacol. 2017 Jan 5;794:20-26. doi: 10.1016/j.ejphar.2016.11.020. Epub 2016 Nov 12.

PMID:
27847179
17.

Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.

Roskoski R Jr.

Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26. Review.

PMID:
27473820
18.

IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics.

Gonzales AJ, Fleck TJ, Humphrey WR, Galvan BA, Aleo MM, Mahabir SP, Tena JK, Greenwood KG, McCall RB.

Vet Dermatol. 2016 Feb;27(1):34-e10. doi: 10.1111/vde.12280. Epub 2015 Dec 15.

19.

Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.

Panteri A, Strehlau G, Helbig R, Prost C, Doucette K.

Vet Dermatol. 2016 Feb;27(1):22-e7. doi: 10.1111/vde.12278. Epub 2015 Dec 11.

20.

An update on the treatment of canine atopic dermatitis.

Saridomichelakis MN, Olivry T.

Vet J. 2016 Jan;207:29-37. doi: 10.1016/j.tvjl.2015.09.016. Epub 2015 Sep 16. Review.

PMID:
26586215

Supplemental Content

Loading ...
Support Center